NCT00916110

Study Of Single Dose Of ATN-103 Administered To Healthy Japanese Male Subjects

Ascending Single Dose Study Of The Safety, Tolerability, PK And PD Of ATN-103 Administered SC Or IV To Healthy Japanese Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: Ablynx, a Sanofi company · Industry
• Sex: Male
• Age: 20 Years – 45 Years
• Healthy volunteers: Accepted

Summary

To assess the safety and tolerability of ascending single SC and IV doses of ATN-103 in healthy Japanese male subjects.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	ATN-103	1.5 mg solution, single subcutaneous injection
DRUG	ATN-103	4 mg solution, single subcutaneous injection
DRUG	ATN-103	10 mg solution, single subcutaneous injection
DRUG	ATN-103	25 mg solution, single subcutaneous injection
DRUG	ATN-103	25 mg solution, single intravenous injection
DRUG	ATN-103	50 mg solution, single subcutaneous injection
DRUG	ATN-103	100 mg solution, single subcutaneous injection
DRUG	ATN-103	200 mg solution, single subcutaneous injection
DRUG	ATN-103	200 mg solution, single intravenous injection

Timeline

• Start date: 2008-11-01
• Primary completion: 2009-11-01
• Completion: 2009-11-01
• First posted: 2009-06-09
• Last updated: 2013-01-16

Locations

1 site across 1 country: Japan